Antion Biosciences
Antion Biosciences SA is a Swiss cell and gene engineering company that licenses its proprietary Multiplex Engineering Platform — a gene modulation technology — to pharmaceutical and biotechnology companies developing cell and gene therapies.
- Company typePrivate
- Founded2016
- HeadquartersGeneva, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingServices
Antion Biosciences firmographics
Firmographics- Name
- Antion Biosciences
- Legal name
- Antion Biosciences SA
- Website
- https://antionbio.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Antion Biosciences SA is a Swiss cell and gene engineering company that licenses its proprietary Multiplex Engineering Platform — a gene modulation technology — to pharmaceutical and biotechnology companies developing cell and gene therapies.
- Ownership category
- akta.pro rank
Antion Biosciences industry classification
Industry- Product category
- Cell and Gene Therapy Technology
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
- akta.pro secondary industries
- Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE)
Keywords
Where Antion Biosciences is headquartered
LocationHeadquarters
- HQ city
- Geneva
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Antion Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
Revenue model
- Technology Licensing and Partnership Services: Antion Biosciences appears to generate revenue through licensing its proprietary multiplex engineering platform technology to pharmaceutical and biotech companies developing cell and gene therapies, as well as through partnership arrangements and services.
Go-to-market motion1 record
Marketing channels2 records
Antion Biosciences product offering
Product offeringCore offering
Antion Biosciences develops a proprietary multiplex engineering platform for gene modulation, enabling the next generation of allogeneic cell and gene therapies. The platform combines surgical precision, enhanced safety, tunable gene regulation, robust multiplexing, high cellular homogeneity, and scalable manufacturing compatibility to address key challenges in therapeutic development. The company licenses this technology and partners with pharmaceutical and biotech firms.
Differentiator
Problem solved
Functional benefit
Products and services
- Multiplex Engineering Platform
Companies that use Antion Biosciences
Customer profileSegments1 record
Ideal customer profiles1 record
Antion Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Antion Biosciences partnerships and signals
Strategic signalScale indicators1 record
Antion Biosciences competitors and assessment
Company assessmentDirect peers
- Century Therapeutics: Century Therapeutics is a clinical-stage biotechnology company developing allogeneic iPSC-derived cell therapies using multiplexed gene editing — directly comparable to Antion's multiplex engineering platform targeting allogeneic cell therapy.
- Cellectis: Cellectis is a clinical-stage gene-editing and cell therapy company developing allogeneic CAR-T platforms using its proprietary TALEN-based gene editing technology — directly comparable to Antion's multiplex engineering approach for allogeneic cell engineering.
- Allogene Therapeutics: Allogene is both a major investor in Antion and a leading allogeneic CAR-T cell therapy developer. It is directly relevant because it is the most visible adopter of Antion's multiplex engineering platform and represents both an exit pathway and a primary commercial customer.
- Caribou Biosciences: Caribou is a CRISPR-based genome editing platform company developing allogeneic CAR-T cell therapies, comparable to Antion in combining a multiplex gene-editing platform with internal allogeneic cell therapy programs.
- Poseida Therapeutics: Poseida is a clinical-stage cell and gene therapy company developing allogeneic CAR-T therapies using its non-viral piggyBac DNA modification platform — directly comparable to Antion in pursuing multiplex, manufacturing-scalable engineering for allogeneic cell therapies.
Broad incumbents
- Intellia Therapeutics: Intellia is a clinical-stage gene-editing company developing both in vivo and ex vivo CRISPR/Cas9-based therapies. It is a broad incumbent comparable to Antion in the gene-editing platform category but with substantially more capital and clinical maturity.
- Sangamo Therapeutics: Sangamo is a genomic medicine company developing zinc finger nuclease-based gene-editing and cell therapy programs. As a broad incumbent gene-editing platform, Sangamo competes for similar pharma licensing deals and cell-engineering partnerships.
- Editas Medicine: Editas Medicine is a clinical-stage gene editing company using CRISPR-based technology to develop therapeutics — a broad incumbent in the gene-editing platform space with deeper capital, IP, and clinical assets than Antion.
- CRISPR Therapeutics: CRISPR Therapeutics is a leading gene-editing company developing CRISPR/Cas9-based therapeutics across hemoglobinopathies, oncology, and regenerative medicine — a broad incumbent competing for the same gene-editing licensing and partnership opportunities as Antion.
- Beam Therapeutics: Beam Therapeutics is a precision genetic medicine company developing base-editing therapies. As a next-generation gene-editing platform, Beam competes with Antion for the same pharma licensing and cell-engineering partnership opportunities.
Market position
Customer concentration
Antion Biosciences social profiles
Digital presenceAntion Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Antion Biosciences leadership team
Management profileNumber of profiles
Profiles3 records
Antion Biosciences funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Antion Biosciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Antion Biosciences
What does Antion Biosciences do?
Antion Biosciences develops a proprietary multiplex engineering platform for gene modulation, enabling the next generation of allogeneic cell and gene therapies. The platform combines surgical precision, enhanced safety, tunable gene regulation, robust multiplexing, high cellular homogeneity, and scalable manufacturing compatibility to address key challenges in therapeutic development. The company licenses this technology and partners with pharmaceutical and biotech firms.
Is Antion Biosciences a public or private company?
Antion Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Antion Biosciences founded?
Antion Biosciences was founded in 2016. It employs 11 to 50 people.
Where is Antion Biosciences based?
Antion Biosciences is headquartered in Geneva, Switzerland, in the Europe region.
How does Antion Biosciences make money?
One revenue line is on record: technology Licensing and Partnership Services.
Who are Antion Biosciences's main competitors?
Direct peers on record are Century Therapeutics, Cellectis, Allogene Therapeutics, Caribou Biosciences and Poseida Therapeutics. Broad incumbents are Intellia Therapeutics, Sangamo Therapeutics, Editas Medicine, CRISPR Therapeutics and Beam Therapeutics.
Does Antion Biosciences have an API?
No public API is recorded for Antion Biosciences.
What industry is Antion Biosciences in?
Antion Biosciences's product category is Cell and Gene Therapy Technology. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 541714 and its SIC code is 2836.